

**REMARKS**


The claims are 14-16, with claim 14 being the sole independent claim. Support for claims 14-16 may be found in original claims 10-13 and in the specification at page 5, lines 9-12. No new matter has been added.

Previously pending claims 1-13 were subject to a restriction requirement and an election requirement. Restriction to one of Groups I-V was required under 35 U.S.C. §121 and 372. Applicants were also required to make an election of anticoagulant species.

Applicants elect the subject matter of Group V, directed to a method of using Argatroban and a coumarin derivative to treat patients with or at risk for HIT, for prosecution in the subject application, without traverse. Accordingly, Argatroban is the anticoagulant species selected for prosecution. New claims 14-16 are directed to the subject matter of elected Group V.

Applicants retain the right to file divisional applications directed to the non-elected subject matter.

Respectfully submitted,



Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090  
N:\KLS\Cases\PU60401\restriction\_requirement.doc